Analyst
Key Indices
Top Stories
Sector Update | China Healthcare
The HSHCI fell 10.6% during 1-15 October, significantly underperforming the HSI, mainly due to profit-taking. Insilico, XtalPi, Akeso, WuXi Bio, which have led outperformers in previous weeks, were the major laggards. Chinese biopharmas will deliver their strongest ESMO showing yet, with 29 studies accepted as late-breaking abstracts. With market focus shifting from business development to robust Phase III data delivery, China's innovation strength should continue to support the sector's positive outlook. Maintain MARKET WEIGHT.
Top Stories
Sector Update | China Healthcare
The HSHCI fell 10.6% during 1-15 October, significantly underperforming the HSI, mainly due to profit-taking. Insilico, XtalPi, Akeso, WuXi Bio, which have led outperformers in previous weeks, were the major laggards. Chinese biopharmas will deliver their strongest ESMO showing yet, with 29 studies accepted as late-breaking abstracts. With market focus shifting from business development to robust Phase III data delivery, China's innovation strength should continue to support the sector's positive outlook. Maintain MARKET WEIGHT.
Analyst
Key Indices
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
